Search results
Showing 931 to 945 of 2186 results for guidelines
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management.
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)
Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
GPs help to bring a primary care perspective to the guidance that we produce.
GPs help to bring a primary care perspective to the guidance that we produce.
NICE has developed a medtech innovation briefing (MIB) on Fungitell for antifungal treatment stratification .
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Benralizumab for treating severe eosinophilic asthma (TA565)
Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma in adults.
This indicator covers the percentage of adults and young people at a GP surgery in an area of high or extremely high HIV prevalence who have not had an HIV test in the last 12 months, who are having a blood test and receive an HIV test at the same time. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM190
This indicator covers the percentage of adults and young people newly registered with a GP in an area of high or extremely high HIV prevalence who receive an HIV test within 3 months of registration. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM189
The geko device for reducing the risk of venous thromboembolism (HTG344)
Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism.
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.